ALVO

Alvotech

ALVO, USA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

https://www.alvotech.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALVO
stock
ALVO

Alvo Minerals Seeks Quotation of Additional Shares on ASX TipRanks

Read more →
ALVO
stock
ALVO

Assessing Alvotech (ALVO) Valuation After FDA Setback And Securities Investigation Concerns simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$22.1667

Analyst Picks

Strong Buy

2

Buy

0

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

21.39

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

-8.17

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

2.95 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.37 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-65.38 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 3.25% of the total shares of Alvotech

1.

Vanguard Total Intl Stock Index Inv

(0.5014%)

since

2025/07/31

2.

Vanguard Emerging Mkts Stock Idx Inv

(0.4416%)

since

2025/07/31

3.

T. Rowe Price International Discovery

(0.3668%)

since

2025/07/31

4.

T. Rowe Price International Small-Cap Eq

(0.3424%)

since

2025/06/30

5.

Eaton Vance Emerg & Frntr Countrs Eq I

(0.2796%)

since

2025/07/31

6.

Vanguard Instl Ttl Intl Stk Mkt Idx TrII

(0.2579%)

since

2025/07/31

7.

iShares Biotechnology ETF

(0.2093%)

since

2025/08/31

8.

L&G Frontier Markets Eq Z USD Acc

(0.1818%)

since

2025/07/31

9.

Eaton Vance Glbl Macro Abs Ret Advtg I

(0.1552%)

since

2025/04/30

10.

T. Rowe Price Intl Small-Cap Eq Tr-C

(0.0812%)

since

2025/06/30

11.

Vanguard FTSE All-Wld ex-US ETF

(0.073%)

since

2025/07/31

12.

Eaton Vance Strategic Income Class C

(0.0613%)

since

2025/04/30

13.

Fidelity Nasdaq Composite Index

(0.0527%)

since

2025/07/31

14.

iShares Nasdaq US Biotech ETF USD Acc

(0.0504%)

since

2025/08/31

15.

Schwab Emerging Markets Equity ETFâ„¢

(0.0428%)

since

2025/08/30

16.

Vanguard Instl Ttl Intl Stck Mkt Idx Tr

(0.0395%)

since

2025/07/31

17.

Eaton Vance Glbl Macr Absolute Return I

(0.039%)

since

2025/04/30

18.

Morgan Stanley Global Macro Abs. Return

(0.0287%)

since

2025/03/31

19.

Vanguard Total World Stock ETF

(0.0244%)

since

2025/07/31

20.

SSGA Emerging Markets Equity Index

(0.023%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.0833

Latest Release

Date

2025-09-30

EPS Actual

-0.0174

EPS Estimate

0.04

EPS Difference

-0.0574

Surprise Percent

-143.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.